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Background: Fertility is an important issue for long-term survivors of malignancies developing during reproductive
years. We designed a population-based study to investigate childbirth in female young adult survivors of
non-gynecologic malignancies.
Methods: Women 20–34 years diagnosed with non-gynecologic malignancies in Ontario from 1992–1999 who
lived at least 5 years recurrence-free were identified using the Ontario Cancer Registry and age matched to 5
randomly selected cancer-free women. Childbirth was determined through hospital discharge data.
Time-to-childbirth was compared between survivors and controls using Cox proportional hazard regression for all
subjects and stratified by prior childbirth and disease site.
Results: 3,285 survivors and 15,118 control women had a median of 12 years observation. 1,194 survivors and 6,049
controls experienced childbirth to the end of observation (March 2011). Overall, survivors experienced a longer time
to childbirth than controls (HR 0.92, 95% CI 0.87-0.98), however this was limited to survivors with prediagnosis
childbirth (HR 0.76, 95% CI 0.66-0.86). Survivors with no prediagnosis childbirth experienced a similar time to
childbirth (HR 1.00, 95% CI 0.93-1.08) as control women. Differences between survivors and controls varied by type
of malignancy; notably for those with prediagnosis childbirth, survivors of breast cancer (HR 0.45, 95% CI 0.29-0.68)
and Hodgkin Disease (HR 0.57, 95% CI 0.36-0.91) had lower rates of postdiagnosis childbirth than controls.
Conclusions: Long-term female young adult survivors of malignancies are less likely than controls to have childbirth
after diagnosis; the overall effect is small and is influenced by prediagnosis childbirth and malignancy type.
Keywords: Cancer survivorship, Young adults, Pregnancy outcomes, Cohort studyBackground
Future fertility is important to many long-term survivors
of malignancies that develop in the peak years of
reproduction. With increasing numbers of women having
children at later ages, even more cancer survivors will face
this issue [1]. In recognition of the importance of future
fertility, the American Society of Clinical Oncology pub-
lished guidelines recommending discussion of the risk of
infertility as a consequence of cancer treatment and* Correspondence: baxtern@smh.toronto.on.ca
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reproduction in any medium, provided the orreferral for consideration of fertility preservation techni-
ques when appropriate [2]. Although fertility is a common
concern for young adult survivors (YAS) of malignancy
and the clinicians caring for them, there are relatively few
population-based studies addressing this issue in the lit-
erature. Studies from Finland [3] and Norway [4,5] dem-
onstrate reduced fertility in the YAS population as
compared to the general population or matched controls,
however these studies include patients diagnosed over a
long time period (as early as 1953 [3]) and reflect treat-
ment regimens that have changed over time. Additionally,
these studies include all patients who developed a malig-
nancy at a young age including those with advanced dis-
ease and patients with rapid recurrence after treatmenttd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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vors. Fertility of 5-year female survivors of childhood can-
cers has been evaluated as part of the Childhood Cancer
Survivor Study [6]. Compared to sibling controls, the rela-
tive risk for female survivors ever being pregnant was 0.81
(95% confidence interval 0.73-0.90), but these findings
have limited application to the YAS population. Other
published studies include patients diagnosed with a single
type of malignancy, and tend to be small, uncontrolled
single institutions reports [7-10]. We therefore designed
this study to evaluate childbirth in a population-based
group of female young adult survivors of malignancy in
Ontario Canada compared with matched control partici-
pants without a cancer diagnosis.
Methods
We designed a retrospective, population-based cohort
study using a provincial cancer registry linked to admin-
istrative data sets.
Data sources
We used four data sources:
1. The Ontario Cancer Registry (OCR) includes
information on all incident cancers diagnosed since
1964 in Ontario. Reporting is provincially mandated
and over 95% complete [11]. The OCR does not
maintain information on tumor stage and does not
contain treatment information.
2. The Ontario Health Insurance Plan (OHIP) database
contains information on claims billed by physicians
for services, permitting identification of virtually all
medical procedures occurring in Ontario.
3. The Canadian Institute for Health Information
Discharge Abstract Database (CIHI-DAD), contains
information on every patient discharged from a
hospital or same-day surgery unit in Ontario and is
highly accurate for admissions for pregnancy and
childbirth [12].
4. The Registered Persons Database (RPBB) is a roster
of all OHIP beneficiaries (virtually all individuals
living in Ontario) and includes demographic
information and length of eligibility.
Diagnostic and procedure codes used in this study are
presented in Additional file 1.
Selection of survivors
Female YAS were identified using the OCR. While the
definition of a YAS varies [13], we limited our cohort to
women age 20 through 34 at diagnosis. All female young
adults registered in the OCR between 1992 (when data-
sets became reliably linkable) and 1999 (to enable sub-
stantive follow up for all 5 year survivors) were eligiblefor inclusion. Women were excluded if they died within
five years of diagnosis, were diagnosed with a gynaeco-
logical malignancy, were registered in OCR for a previ-
ous malignancy, or were not continuously eligible for
provincial health insurance coverage for at least seven
years after diagnosis (or until death).Identification of recurrence
Recurrence of malignancy is likely to have an influence on
childbearing but the OCR does not include information
on cancer recurrence. We therefore developed an algo-
rithm to identify survivors with evidence of recurrent dis-
ease from physician claims and diagnostic codes based on
use of chemotherapy, palliative care, or diagnosis of meta-
static disease (Additional file 1). Patients with a solid
tumor malignancy undergoing a second course of chemo-
therapy (or third course in the case of hematologic malig-
nancies) after completion of adjuvant therapy, or delivery
of a first course of chemotherapy more than 6 months
after completion of cancer directed surgery were consid-
ered to have disease recurrence. Survivors identified with
recurrent disease within the first 5 years of diagnosis were
excluded entirely. Survivors developing recurrent disease
after 5 years of survivorship were censored 6 months be-
fore the date recurrence was identified as the exact date of
recurrence could not be obtained.Selection of controls
A female control population was selected using the
RPDB. Eligible women from the general population were
matched to the survivors based on calendar year of birth
and geographic location. Five controls were randomly
selected without replacement from all potential controls
matched to a given survivor. Controls were assigned a
referent date that corresponded to the date of diagnosis
in the matched survivor. Controls were excluded if they
had a diagnosis of cancer prior to the referent date
(determined through linkage with the OCR), died within
five years of the referent date, or were not continuously
eligible for provincial health insurance for at least seven
years after the referent date.Identification of surgical sterilization
We identified women who had undergone a procedure
consistent with surgical sterilization (tubal ligation, bilat-
eral oophorectomy, hysterectomy) based on OHIP and
CIHI-DAD codes. Survivors and controls with evidence
of surgical sterilization at any time prior to diagnosis or
up to 12 months after diagnosis or referent date were
excluded. Individuals undergoing surgical sterilization
more than 1 year after diagnosis or referent date were
censored on the date of surgical sterilization.
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We identified admission for childbirth for all members of
our cohort from Jan 1, 1987 through March 31, 2011 from
information from CIHI-DAD. Delivery of an infant, live or
stillborn over 20 weeks gestational age, as coded in CIHI
was considered evidence of childbirth for this study.Covariates
For survivors and controls we determined income quin-
tile, defined by the census dissemination area where
individuals lived at the date of diagnosis or referent date.
We considered childbirth prior to the date of diagnosis
or referent date a potential covariate. For the survivor
group we evaluated rates of delivery by diagnosis, cat-
egorizing survivors into broad groups including the diag-
noses with at least 100 women (brain, breast, Hodgkin
lymphoma, non-hodgkin lymphoma [NHL], melanoma,
thyroid and other malignancies).Analysis
We calculated descriptive statistics for study variables
stratified for survivors and controls. The outcome of inter-
est was childbirth occurring at least one year after the date
of diagnosis (survivors) / referent date (controls). The one
year interval was used to ensure that childbirth was a result
of post-diagnosis pregnancy. We calculated the time be-
tween diagnosis or referent date to the time of admission
to hospital for childbirth for each subject. Patients were
censored at death, loss-to-follow-up, surgical sterilization,
6 months prior to evidence of recurrent disease, or March
31, 2011, whichever came first. Multivariate analyses with
the Cox proportional hazards regression model were con-
ducted to evaluate the relationship between time to child-
birth and covariates such as YAS (yes or no), income
quintile, age (treated as continuous), and previous child-
birth (children born prior to diagnosis or referent date, yes
or no). did not consider childbirth from 0–12 months from
diagnosis/referent date in our analysis. We tested the inter-
action between the survivor indicator and previous child-
birth. Since this interaction term was highly significant, we
further matched survivors and corresponding controls on
previous childbirth and stratified the analysis based on this
variable. That is, the first and second stratum consists of
all survivors and corresponding matched controls with and
without, respectively, children born prior to diagnosis or
referent date. The Cox regression model for each stratum
included YAS, income quintile, and age. To account for
the matched design with a variable number of controls per
survivor (due to further matching by previous childbirth),
we used a robust sandwich variance estimator approach to
estimate the standard errors of the Cox regression param-
eter estimates [14]. The proportional hazards assumption
was tested and was not violated. We repeated the analysiswithout censoring patients for recurrence after 5 years as a
sensitivity analysis.
We analyzed data using SAS version 9.2 (Cary, North
Carolina). All statistical tests were two-sided, and p-values
less than 0.05 were considered statistically significant. The
study was approved by the Research Ethics Board of St.
Michael’s Hospital, Toronto, Ontario. All data analysis was
conducted at the Institute for Clinical Evaluative Sciences,
a Section 45 (1) prescribed entity in Ontario’s Personal
Health Information Protection Act. The data used are not
freely accessible; permission for the use of the data was
given by the Institute for Clinical Evaluative Sciences.
Results
We identified 5,172 women age 20 through 34 who devel-
oped a non-gynecologic invasive malignancy between Jan
1, 1992 and Dec 31, 1999 based on registration in the
OCR. Of these, 3,536 survived at least 5 years after diagno-
sis with no evidence of recurrence in administrative data
and were continuously eligible for health insurance in On-
tario until death or at least 7 years after diagnosis. There
were 3,2 85 YAS after all exclusion criteria were applied
(consort diagram) Additional file 2. We selected 15,176
matched controls from a potential control population of
2,660,134 women. The characteristics of the survivors and
controls are presented in Table 1. The majority of survi-
vors had breast cancer (18%), thyroid cancer (27%) or mel-
anoma (15%) (Table 2).
A total of 1,194 of survivors delivered 1,910 children in
the period from 1 year after diagnosis to the end of follow
up vs. 6,049 controls who delivered 9,516 children. Survi-
vors in our cohort were less likely than controls to be ad-
mitted for childbirth starting 12 months or more after
diagnosis (Figure 1); the cumulative rate of childbirth at
10-years in the survivor group was 36.3% vs. 39.9% in the
control group (p < 0.001). After adjusting for socioeco-
nomic status and age in our multivariate model, time to
childbirth was significantly longer for survivors than con-
trols (HR 0.92, 95% CI 0.87–0.98) (Table 3). Childbirth
prior to diagnosis influenced time to childbirth after diag-
nosis (Figure 1); to further evaluate this relationship we
stratified our survivors by known childbirth prior to diag-
nosis and included only controls with a similar history
prior to the referent date. There were 1,093 survivors and
2,066 matched controls with childbirth prior to the diag-
nosis/referent date and 2,192 survivors and 6,937 matched
controls without childbirth prior to the diagnosis/referent
date. As compared to controls, survivors with prior child-
birth were less likely to experience a delivery over time
(HR 0.76, 95% CI 0.66–0.86) while survivors without prior
childbirth had a similar rate of childbirth (HR 1.00, 95% CI
0.92–1.08) (Table 3). The results did not change when we
did not censor 5-year survivors 6 months prior to evidence
of recurrence.
Table 2 Rates of childbirth 12 months after diagnosis / referent date over time




Mean # Postdiagnosis Deliveries Cumulative 10-year Rate of Childbirth (%)
Survivors Controls Survivors Controls
Brain 142 (4.3) 35.9 0.42 0.72 31.2 41.6
Breast 588 (17.9) 34.5 0.30 0.43 22.5 29.9
Hodgkin Lymphoma 358 (10.9) 22.9 0.82 0.81 43.2 46.4
Non-Hodgkin Lymphoma 204 (6.2) 22.6 0.53 0.60 34.6 37.6
Thyroid 890 (27.1) 36.7 0.67 0.67 40.8 41.4
Melanoma 498 (15.2) 36.1 0.69 0.63 41.1 39.9
Other 605 (18.4) 33.7 0.57 0.64 35.6 38.9
Table 1 Characteristics of female young adult survivors and their matched controls













Age, Mean (SD) 28.8 (4.1) 28.6 (4.1) 30.1 (3.3) 30.8 (2.8) 28.1 (4.3) 27.3 (4.4)
Median Follow-up in survivors without childbirth 12.4 13.0 11.7 11.9 12.8 13.6
Diagnosis Year (%)
1992 397 (12.1) 92 (8.3) 305 (13.9)
1993 387 (11.8) 109 (10.0) 278 (12.7)
1994 386 (11.8) 110 (10.0) 276 (12.6)
1995 400 (12.2) 142 (12.4) 258 (11.8)
1996 385 (11.7) 134 (12.3) 251 (11.4)
1997 410 (12.5) 150 (13.8) 260 (11.9)
1998 441 (13.4) 177 (16.3) 264 (12.0)
1999 479 (14.6) 179 (17.0) 300 (13.7)
Income Quintile (%)
1 (lowest) 662 (20.2) 3138 (20.7) 210 (19.2) 395 (19.1) 452 (20.6) 1413 (20.4)
2 677 (20.6) 3269 (21.5) 214 (19.6) 425 (20.6) 463 (21.1) 1502 (21.7)
3 644 (19.6) 3066 (20.2) 218 (20.0) 423 (20.5) 426 (19.4) 1381 (19.9)
4 681 (20.7) 2975 (19.6) 246 (22.5) 465 (22.5) 435 (19.8) 1315 (19.0)
5 (highest) 621 (18.9) 2728 (18.0) 205 (18.8) 358 (17.3) 416 (19.0) 1326 (19.1)
Surgical Sterilization 12 months or more after Diagnosis or Referent Date (%)
Yes 637 (19.4) 2,609 (17.2) 305 (27.9) 520 (25.2) 332 (15.1) 855 (12.3)
No 2,648 (80.6) 12,567 (82.8) 788 (72.1) 1,546 (74.8) 1,860 (84.9) 6,082 (87.7)
Childbirth prior to diagnosis or Referent Date (%)
Yes 1,093 (33.3) 5,342 (35.2) 1,093 (100) 2,066 (100)
No 2,192 (66.7) 9,834 (64.8) 2,192 (100) 6,937 (100)
Childbirth 12 months or more after Diagnosis or Referent Date (%)
Yes 1,194 (36.3) 6,049 (39.9) 336 (30.7) 716 (34.7) 858 (39.1) 2,983 (43.0)
No 2,091 (63.7) 9,127 (60.1) 757 (69.3) 1,350 (65.3) 1,334 (60.9) 3,954 (57.0)
Mean number of deliveries
12 Months or more post diagnosis/referent date 0.58 0.63 0.39 0.43 0.68 0.76
At any time pre or post diagnosis/referent date 1.05 1.12 1.80 1.87 0.68 0.76
Cumulative 10-year delivery rate 36.3 39.1 32.5 36.2 38.0 40.4
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Figure 1 Time to childbirth at least 12 months post diagnosis / referent date. The blue line represents the YAS and the black line
represents the control group.
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Table 3 Results of multivariable cox proportional hazards model evaluating time to childbirth more than 1 year after
diagnosis/referent date by survivor status
Variable Overall Women with childbirth before diagnosis Women with no childbirth before diagnosis
HR 95% CI p value HR 95% CI p value HR 95% CI p value
Survivor Status
YAS 0.92 0.87–0.98 0.007 0.76 0.66–0.86 <0.001 1.00 0.93–1.08 0.93
Control 1 Referent 1 Referent 1 Referent
Income Quintile
1 0.89 0.83–0.95 0.001 0.70 0.57–0.86 <0.001 0.85 0.77–0.94 0.002
2 0.92 0.86–0.99 0.02 0.72 0.59–0.89 0.002 0.94 0.86–1.04 0.23
3 0.94 0.87–1.01 0.08 0.84 0.69–1.02 0.09 0.90 0.82–0.99 0.04
4 1.00 0.93–1.07 0.95 0.86 0.70–1.04 0.12 1.01 0.92–1.11 0.89
5 1 Referent 1 Referent 1 Referent
Age 0.91 0.90–0.91 <0.001 0.86 0.85–0.88 <0.001 0.91 0.91–0.92 <0.001
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vivor status varied by diagnosis (Table 3, Figure 2); not-
ably for those with prior childbirth, YAS with breast
cancer (HR 0.45, 95% CI 0.29–0.68) or Hodgkin disease
(HR 0.57, 95% CI 0.36–0.91) were statistically signifi-
cantly less likely to experience childbirth than controls.
In contrast, a cancer diagnosis had no statistically sig-
nificant impact for other YAS groups. Notably, women
with thyroid cancer and melanoma experienced very
similar rates of childbirth as control women (cumulative
10-year rate of child birth in YAS with thyroid cancer
40.8% vs. controls 41.4% and in YAS with melanoma
41.1% vs. 39.9%)
Discussion
In this population based study of young female survivors
of non-gynecological malignancy, time to childbirth was
greater than age-matched women with no history of malig-
nancy; as compared to matched controls over a median ob-
servation time period of 12 years after diagnosis although
the difference was small (HR 0.92, 95% CI 0.87–0.98). Not-
ably, the relationship between childbirth and survivor sta-
tus varied significantly by history of previous childbirth;
survivors with no history of previous childbirth actually
had a similar likelihood of postdiagnosis childbirth as
matched controls, while for those with children postdiag-
nosis childbirth was reduced by 24%.
There are 3 previously published population-based
studies of pregnancy and parenthood after a diagnosis of
any malignancy in young adults [3-5]; all included
patients diagnosed from the 1960s. Only one study, con-
ducted in Norway [5], included all survivors irrespective
of parenthood status before diagnosis and found, similar
to our study, a significant relationship between previous
pregnancy and the rate of postdiagnosis pregnancy –
overall the rate of pregnancy was lower in female cancer
patients than controls (HR 0.61) however this was morepronounced for women with a child prior to diagnosis
(HR 0.52) than for those without a child (HR 0.73). A
large cohort study of young adults treated at a single in-
stitution in Norway [15,16] demonstrated similar find-
ings. Variations in attitudes towards parenthood may be
the cause of this finding. Perceptions of young adult can-
cer survivors with respect to fertility has been found to
vary with parenthood status; childless survivors have
been found more likely to desire future children and are
less likely to perceive that the diagnosis of cancer has
negatively influenced their desire for future children
than survivors with children [17].
The two additional population-based studies [3,4] eval-
uated first time parenthood (i.e. deliveries in survivors
with no children prior to diagnosis) in survivors. Syse et
al [4] demonstrated a 27% reduction in parenthood in
women diagnosed with cancer between age 17–44 as
compared to the population while Madanat [3] demon-
strated a 54% reduction in parenthood in women diag-
nosed with cancer between age 0–34 as compared to
sibling controls. These studies demonstrated a greater
impact of cancer diagnosis on postdiagnosis pregnancy
or parenthood than ours and this may be explained in a
number of ways. The studies were not limited to patients
surviving cancer, and they therefore included individuals
with advanced disease at diagnosis, those with limited
life expectancy and patients who developed recurrence
within a short period of follow up. Such patients would
be expected to have a lower rate of pregnancy than
long-term survivors. Additionally, these studies included
patients diagnosed over a long period of time – all found
higher rates of pregnancy in young adult patients treated
in more contemporaneous time periods, although follow
up of patients in the later time periods in these studies
was limited. Finally, we did not include patients with
gynaecologic malignancies, a group most likely to
undergo surgical sterilization as part of treatment.
All Survivors and Controls 
Survivors and Controls with Pre-Diagnosis Childbirth 
 Survivors and Controls with No Pre-Diagnosis Childbirth  
Legend: 
NHL = Non-hodgkin lymphoma
YAS = Young Adult Survivors
HR = Hazards Ration




Figure 2 Results of multivariable cox proportional hazards
model evaluating time to childbirth at least 12 months after
diagnosis / referent date by survivor status for individual
malignancies controlling for age and SES. Figure 2b: Survivors
and Controls with Pre-Diagnosis Childbirth. Figure 2c: Survivors and
Controls with No Pre-Diagnosis Childbirth.
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livery post-diagnosis. Breast cancer survivors who had a
history of prior childbirth had a marked reduction in the
rate of postdiagnosis childbirth (HR 0.45, 95% CI
0.29–0.68) as compared with controls. There are a num-
ber of factors that may influence the fertility of women
after a diagnosis of breast cancer [18,19]. Many young
women who develop breast cancer receive chemotherapy
to improve their chance of survival but are therefore at
risk of chemotherapy-related amenorrhea, premature
ovarian failure and infertility. Exposure to prolonged hor-
monal therapy in women with ER positive breast cancer
reduces fertility for the duration of exposure. However,
given that women with breast cancer with no prediagnosis
childbirth had similar rates of childbirth to controls (HR
0.90, 95% HR 0.72–1.13) decreased fertility in these
patients is likely an incomplete explanation of our finding.
Although studies have not demonstrated a negative im-
pact of pregnancy on breast cancer outcome [20,21] it is
possible that women may delay or avoid pregnancy for
fear of recurrence with the estrogen stimulation of preg-
nancy; this effect may be more pronounced in women
who have had children. Survivors of Hodgkin Disease who
had prior childbirth were similarly less likely to experience
postdiagnosis deliveries (0.57, 95% CI 0.36–0.91) than
control women. Patients with Hodgkin Disease are fre-
quently exposed to oophorotoxic chemotherapy and pre-
mature ovarian failure is common after bone marrow
transplantation [22]. However, the cumulative 10-year rate
of childbirth in YAS with Hodgkin Disease was substantial
(Hodgkins 43.2%) and only 3.2% lower than matched
controls.
This is a large population-based study and all patients
included were treated since 1990 with therapeutic inter-
ventions more likely to be relevant to today’s survivors
than many previous studies. Additionally, by limiting
our sample to 5 year survivors we excluded most women
with advanced disease, limited life expectancies and early
recurrence, groups with expected lower rates of child-
birth. Inclusion of these women would tend to overesti-
mate the impact of a cancer diagnosis on childbirth for
long-term survivors. Our study, with observation to
March 2011 provides over 10 years of potential follow
up to all women included in the cohort. Our study how-
ever does have limitations. To ensure a contemporary
cohort of 5-year survivors with sufficient follow up we
have restricted our cohort to an 8 year period and there-
fore the sample size for some types of malignancies is
small. Additionally, information regarding childbirth is
available only since 1988 and thus we do not have
complete prediagnosis information for all women. We
do not have access to data on assisted reproduction as
this was not a covered service in Ontario and thus we
do not know if YAS required such services more
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by factors specific to a Canadian context and factors
such as underlying fertility of the population [23] should
be considered prior to generalizing to other jurisdictions.
Finally, we do not have access to detailed information
regarding stage or treatment which would further inform
the analysis.Conclusion
Female survivors of malignancy developing in young adult-
hood overall experience a small reduction in the likelihood
of childbirth after diagnosis over a median of 12 years of
follow up as compared to age matched controls, however
the effect is not homogeneous. Parenthood prior to diag-
nosis modifies the effect of diagnosis – women who did
not have children prior to diagnosis were more likely to ex-
perience childbirth after diagnosis indicating that non-
biologic factors have an important influence in this group.
Survivors of melanoma and thyroid cancer, particularly
those with no history of childbirth, can be reassured by our
findings that for long term survivors reproductive out-
comes do not seem to be affected. However, for women
surviving other forms of malignancies, in particular breast
cancer and Hodgkin Disease there is a reduction in child-
birth even in this comparatively contemporary cohort.
These findings should be considered in pre-treatment
counselling and discussions with patients with respect to
options to preserve fertility in those desiring future preg-
nancies. However, given the association between prediag-
nosis childbirth and the likelihood of childbirth after
diagnosis, non-biologic factors may have an important in-
fluence on the likelihood of having children after a malig-
nant diagnosis in the YAS population.Research support
This research was supported by the Canadian Institutes
for Health Research and the Ontario Ministry of Research
and Innovation. Dr Baxter holds the Cancer Care Ontario
Health Services Research Chair and an Early Researchers
Award from the Ontario Ministry of Research and
Innovation. Dr. Paszat is supported by a clinician scientist
salary from the Ministry of Health and Long-term Care of
Ontario. The funding sources played no role in design,
conduct, or reporting of this study. This study was sup-
ported by the Institute for Clinical Evaluative Sciences,
which is funded by an annual grant from the Ontario
Ministry of Health and Long-Term Care. The opinions,
results and conclusions reported in this paper are those of
the authors and are independent from the funding
sources. No endorsement by the Institute for Clinical
Evaluative Sciences or the Ontario Ministry of Health and
Long-Term Care is intended or should be inferred.Additional files
Additional file 1: Appendix 1. Diagnostic and Procedure Codes used
in the Study.
Additional file 2: Appendix 2. Consort Diagram.
Competing interests
The authors declare that they have no competing interests.
Authors’ contribution
NNB was responsible for study design, analysis and drafting of the
manuscript. RS participated in study design, was responsible for the analysis
and helped to draft the manuscript. EG participated in study design and
helped to draft the manuscript. SF participated in study design and analysis.
FLP participated in study design, analysis and edited the manuscript. ASW
performed the analysis and helped to draft the manuscript. DU participated
in study design and analysis. LR participated in study design, analysis and
edited the manuscript. All authors read and approved the final manuscript.
Author details
1Department of Surgery and Keenan Research Centre, Li Ka Shing
Knowledge Institute, St Michael’s Hospital, University of Toronto, 30 Bond
Street 16CC-40, Toronto, ON M5B 1W8, Canada. 2Institute for Clinical
Evaluative Sciences, Toronto, Canada. 3Institute of Health Policy,
Management, and Evaluation, University of Toronto, Toronto, ON, Canada.
4Department of Family and Community Medicine, University of Toronto,
Toronto, Canada. 5Department of Surgery, McMaster University, Hamilton,
Canada. 6Odette Cancer Centre, Sunnybrook Health Sciences Centre Toronto,
Toronto, Canada. 7Dalla Lana School of Public Health, University of Toronto,
Toronto, Canada. 8Department of Surgery, University Health Network,
Toronto, ON, Canada. 9Cancer Care Ontario, Toronto, Canada.
Received: 2 July 2012 Accepted: 12 January 2013
Published: 23 January 2013
References
1. Births: Statistics Canada “the Daily”; 2011. Available at: http://www.statcan.gc.
ca/daily-quotidien/110427/dq110427a-eng.htm; Accessed June 12 2011.
2. Lee SJ, Schover LR, Partridge AH, Patrizio P, Wallace WH, Hagerty K, Beck LN,
Brennan LV, Oktay K: American society of clinical oncology
recommendations on fertility preservation in cancer patients. J Clin Oncol
2006, 24:2917–2931.
3. Madanat LM, Malila N, Dyba T, Hakulinen T, Sankila R, Boice JD Jr,
Lahteenmaki PM: Probability of parenthood after early onset cancer: a
population-based study. Int J Cancer 2008, 123:2891–2898.
4. Syse A, Kravdal O, Tretli S: Parenthood after cancer - a population-based
study. Psychooncology 2007, 16:920–927.
5. Stensheim H, Cvancarova M, Moller B, Fossa SD: Pregnancy after
adolescent and adult cancer: A population-based matched cohort study.
Int J Cancer 2011, 129(5):1225–1236.
6. Green DM, Kawashima T, Stovall M, Leisenring W, Sklar CA, Mertens AC,
Donaldson SS, Byrne J, Robison LL: Fertility of female survivors of
childhood cancer: a report from the childhood cancer survivor study. J
Clin Oncol 2009, 27:2677–2685.
7. Fridrichova M, Dienstbier Z, Loucka M, Skala E, Blomannova E: Long-term
survival of patients treated for Hodgkin’s disease in 1971–1996
depending on the clinical stage of the disease, patient’s fertility after
therapy and cause of death analysis. Neoplasma 2009, 56:480–485.
8. Hodgson DC, Pintilie M, Gitterman L, Dewitt B, Buckley CA, Ahmed S, Smith
K, Schwartz A, Tsang RW, Crump M, Wells W, Sun A, Gospodarowicz MK:
Fertility among female hodgkin lymphoma survivors attempting
pregnancy following ABVD chemotherapy. Hematol Oncol 2007, 25:11–15.
9. Elis A, Tevet A, Yerushalmi R, Blickstein D, Bairy O, Dann EJ, Blumenfeld Z,
Abraham A, Manor Y, Shpilberg O, Lishner M: Fertility status among
women treated for aggressive non-Hodgkin’s lymphoma. Leuk Lymphoma
2006, 47:623–627.
10. Franchi-Rezgui P, Rousselot P, Espie M, Briere J, Pierre Marolleau J,
Gisselbrecht C, Brice P: Fertility in young women after chemotherapy with
alkylating agents for Hodgkin and non-Hodgkin lymphomas. Hematol J
2003, 4:116–120.
Baxter et al. BMC Cancer 2013, 13:30 Page 9 of 9
http://www.biomedcentral.com/1471-2407/13/3011. Robles SC, Marrett LD, Clarke EA, Risch HA: An application of capture
recapture methods to the estimation of completeness of cancer
registration. J Clin Epidemiol 1988, 41:495–501.
12. Canadian Institute for Health Information Data Quality Study of the 2009–2010
Discharge Abstract Database; 2012. Available at: https://secure.cihi.ca/
free_products/Reabstraction_june19revised_09_10_en.pdf; Accessed December
26 2012.
13. Theis B, Nishri D, Bahl S, Ugnat A, Marrett L: Cancer in Young Adults in
Canada Toronto, Canada.: Cancer Care Ontario; 2006.
14. Lin DY, Wei LJ: The robust inference for the Cox proportional hazards
model. J Am Stat Assoc 1989, 84:1074–1078.
15. Cvancarova M, Samuelsen SO, Magelssen H, Fossa SD: Reproduction rates
after cancer treatment: experience from the Norwegian radium hospital.
J Clin Oncol 2009, 27:334–343.
16. Magelssen H, Melve KK, Skjaerven R, Fossa SD: Parenthood probability and
pregnancy outcome in patients with a cancer diagnosis during
adolescence and young adulthood. Hum Reprod 2008, 23:178–186.
17. Schover LR, Rybicki LA, Martin BA, Bringelsen KA: Having children after
cancer. A pilot survey of survivors’ attitudes and experiences. Cancer
1999, 86:697–709.
18. Peate M, Meiser B, Hickey M, Friedlander M: The fertility-related concerns,
needs and preferences of younger women with breast cancer: a
systematic review. Breast Cancer Res Treat 2009, 116:215–223.
19. Partridge AH, Ruddy KJ: Fertility and adjuvant treatment in young women
with breast cancer. Breast 2007, 16(Suppl 2):S175–S181.
20. Ives A, Saunders C, Bulsara M, Semmens J: Pregnancy after breast cancer:
population based study. BMJ 2007, 334:194.
21. Kroman N, Jensen MB, Wohlfahrt J, Ejlertsen B: Pregnancy after treatment
of breast cancer–a population-based study on behalf of Danish breast
cancer cooperative group. Acta Oncol 2008, 47:545–549.
22. Knopman JM, Papadopoulos EB, Grifo JA, Fino ME, Noyes N: Surviving
childhood and reproductive-age malignancy: effects on fertility and
future parenthood. Lancet Oncol 2010, 11:490–498.
23. Statistics Canada: Crude Birth Rate, Age-Specific and Total Fertility Rates (live
births), Canada, Provinces and Territories Annual (rate); 2012. Available at:
http://www5.statcan.gc.ca/cansim/a05?
lang=eng&id=1024505&paSer=&pattern=102-4505&stByVal=1&csid=;
Accessed December 12 2012.
doi:10.1186/1471-2407-13-30
Cite this article as: Baxter et al.: A population-based study of rates of
childbirth in recurrence-free female young adult survivors of Non-
gynecologic malignancies. BMC Cancer 2013 13:30.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
